Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by State Street Corp

State Street Corp reduced its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,165,182 shares of the biopharmaceutical company’s stock after selling 46,127 shares during the quarter. State Street Corp owned 2.00% of Vanda Pharmaceuticals worth $5,465,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Meeder Asset Management Inc. purchased a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $39,000. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth about $40,000. China Universal Asset Management Co. Ltd. raised its holdings in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals in the second quarter valued at about $75,000. Finally, Intech Investment Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth approximately $84,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock opened at $4.81 on Friday. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $6.75. The firm has a market capitalization of $280.46 million, a price-to-earnings ratio of -17.18 and a beta of 0.76. The stock’s fifty day moving average is $4.86 and its two-hundred day moving average is $5.18.

Analyst Ratings Changes

A number of analysts recently weighed in on VNDA shares. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Friday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research note on Monday, December 23rd.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.